실데나필 복용 이후 발생한 청색시증에 대한 사례

다국어 초록 (Multilingual Abstract)

The emergence of phosphodiesterase (PDE) 5 inhibitors gave rise to the solution for erectile dysfunction, starting with the development of sildenafil. Although their efficacy in treating erectile dysfunction has been shown, the side effects of PDE5 inhibitors, especially sildenafil, must be taken into consideration. A 64-year-old man received 100 mg of sildenafil and experienced blue vision in both eyes; however, after a day or so, his symptoms improved. The symptoms disappeared when he stopped administering sildenafil, but reappeared when the medication was re-administered. Therefore, he discontinued sildenafil treatment and was prescribed udenafil instead. After that, visual adverse events no longer occurred. Causality assessment showed that in this case, sildenafil-induced cyanopsia was “certain” under the World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria and Korean causality assessment algorithm (Ver.2), and was “probable” according to the Naranjo scale. In addition, sildenafil also led to abnormal visual reactions in other cases. Sildenafil can also inhibit PDE6, which is present in retinal cells, unlike other PDE5 inhibitors. Thus, visual adverse reactions, such as blue vision, are the unique results of sildenafil, and other PDE5 inhibitors may be used to prevent them.

목차 (Table of Contents)

• ABSTRACT
• 고찰
• 결론
• 참고문헌

참고문헌 (Reference)

1 홍경섭, "약물이상반응의 인과성 평가를 위한 한국형 알고리즘의 개발" 대한임상약리학회 10 (10): 129-142, 2002

2 Ministry of Food and Drug Safety Integrated Medicine Information System, "Zydena 100 mg (udenafil)"

3 Li Y-Y, "Visual impairment with possible macular changes after a high dose of sildenafil in a healthy young woman" 11 (11): 340-342, 2018

4 Laties A, "Viagra(sildenafil citrate)and ophthalmology" 21 (21): 485-506, 2002

5 Ebrey T, "Vertebrate photoreceptors" 20 (20): 49-94, 2001

6 Ministry of Food and Drug Safety Integrated Medicine Information System, "VIAGRA® Tablets 50 mg/ 100 mg (sildenafil citrate) 2014"

7 Wallis RM, "Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro" 83 (83): 3-12, 1999

8 World Health Organization (WHO) — Uppsala Monitoring Centre, "The use of the WHO-UMC system for standardized case causality assessment"

9 Wallis RM, "The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5" 114 (114): 22-26, 1999

10 Boolell M, "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction" 8 (8): 47-52, 1996

11 Yanoga F, "Sildenafil citrate induced retinal toxicity-electroetinogram, optical coherence tomography, and adaptive optics findings" 12 (12): S33-S40, 2018

12 Nivison-Smith L, "Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa" 128 : 43-56, 2014

13 Lagnado L, "Signal flow in visual transduction" 8 (8): 995-1002, 1992

14 Ulshafer RJ, "Sensitivity of photoreceptors to elevated levels of cGMP in the human retina" 19 (19): 1236-1241, 1980

15 Tsang SH, "Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase" 272 (272): 1026-1029, 1996

16 Huang SA, "Phosphodiesterase-5 (PDE5) inhibitors In the management of erectile dysfunction" 38 (38): 407-419, 2013

17 Corbin JD, "Pharmacology of phosphodiesterase-5inhibitors" 56 (56): 453-459, 2002

18 Burnett AL, "Nitric oxide in the penis : physiology and pathology" 157 (157): 320-324, 1997

19 Ignarro LJ, "Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle" 170 (170): 843-850, 1990

20 Ames A, 3rd, "Metabolic flux of cyclic GMP and phototransduction in rabbit retina" 406 : 163-179, 1988

21 Feldman HA, "Impotence and its medical and psychosocial correlates : results of the Massachusetts Male Aging Study" 151 (151): 54-61, 1994

22 Pfizer Labs, "Full prescribing information for VIAGRA 2017"

23 Miller WH, "Evidence that cyclic GMP regulates membrane potential in rod photoreceptors" 280 (280): 64-66, 1979

24 Lue TF, "Erectile dysfunction" 342 (342): 1802-1813, 2000

25 Ballard SA, "Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes" 159 (159): 2164-2171, 1998

26 Wespes E, "EAU Guidelines on erectile dysfunction : an update" 49 (49): 806-815, 2006

27 Taylor J, "Differences in side-effect duration and related bother levels between phosphodiesterase type 5inhibitors" 103 (103): 1392-1395, 2009

28 Corbin JD, "Cyclic GMP phosphodiesterase-5: target of sildenafil" 274 (274): 13729-13732, 1999

29 Pugh EN, Jr., "Cyclic GMP and calcium: the internal messengers of excitation and adaptation in vertebrate photoreceptors" 30 (30): 1923-1948, 1990

30 Lolley RN, "Cyclic GMP accumulation causes degeneration of photoreceptor cells : simulation of an inherited disease" 196 (196): 664-666, 1977

31 Ministry of Food and Drug Safety Integrated Medicine Information System, "Cialis 10 mg (tadalafil) 2017"

32 Cote RH, "Characteristics of photoreceptor PDE(PDE6) : similarities and differences to PDE5" 16 (16): S28-S33, 2004

33 Guler S, "Blue vision and sinus tachycardia : sildenafil citrate overdose" 6 : 87-89, 2015

34 Kotera J, "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction" 188 (188): 668-674, 2012

35 Naranjo CA, "A method for estimating the probability of adverse drug reactions" 30 (30): 239-245, 1981